Fenwick Represents Surf Bio in $400M Acquisition by Halozyme

Fenwick represented Surf Bio, a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in its acquisition by Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

The Surf Bio hyperconcentration technology is being developed to enable high concentrations of up to 500 mg/mL across a wide range of therapeutics, including monoclonal antibodies and small molecules, for delivery in a single auto-injector shot for at-home or in-HCP office use. More information can be obtained from the news announcement.

The Fenwick transaction team included corporate partners Effie Toshav and David Michaels, associates Rob O’Connor, David Heckman, Philip Ewing and Max Krinsky and law clerk Andrew Silverstein; technology transactions partner Stefano Quintini and associates Kehl Sink and Kiyan Savar; executive compensation and employee benefits partner Marshall Mort and associates Christophe Delrieu, Melita Chan and Nathan Pope; privacy and cybersecurity partner Ana Razmazma and associate Kayla Tanaka; antitrust and competition partner Steve Alberston and associate Susan Lee; trade and national security partner Robert Slack and associates Brooklynn Moore and Jake Medvitz; and patent counsel Glenn Foulds and scientist Dr. Nadzeya Kukhta.